Abstract
Invasive apocrine carcinoma of the breast is a rare entity with an incidence of 3 or 4 cases per million women. Although apocrine breast cancers may have an aggressive clinical presentation, the 7-year cancer survival rate is the same as non-apocrine cancers. The prognosis of IAC is currently determined by conventional factors such as grade, tumor size, and nodal status. Targeted AR therapy is increasingly adopted with some positive results in clinical trials. This research may result in the development of a tailored treatment for these unusual and rare cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have